Drug news
Komboglyze (BMS/AstraZeneca) is EU approved as a combination for Type 2 Diabetes
The EMA has granted marketing authorisation for Komboglyze from BMS/AstraZeneca, which combines the DPP-4 inhibitor Onglyza (saxagliptin) with metformin in a once-a-day pill.The combo is to be used as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 Diabetes inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of Onglyza and metformin as separate tablets. The FDA approved the combination drug in December 2010
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.